Your browser doesn't support javascript.
loading
White matter hyperintensities and smaller cortical thickness are associated with neuropsychiatric symptoms in neurodegenerative and cerebrovascular diseases.
Ozzoude, Miracle; Varriano, Brenda; Beaton, Derek; Ramirez, Joel; Adamo, Sabrina; Holmes, Melissa F; Scott, Christopher J M; Gao, Fuqiang; Sunderland, Kelly M; McLaughlin, Paula; Goubran, Maged; Kwan, Donna; Roberts, Angela; Bartha, Robert; Symons, Sean; Tan, Brian; Swartz, Richard H; Abrahao, Agessandro; Saposnik, Gustavo; Masellis, Mario; Lang, Anthony E; Marras, Connie; Zinman, Lorne; Shoesmith, Christen; Borrie, Michael; Fischer, Corinne E; Frank, Andrew; Freedman, Morris; Montero-Odasso, Manuel; Kumar, Sanjeev; Pasternak, Stephen; Strother, Stephen C; Pollock, Bruce G; Rajji, Tarek K; Seitz, Dallas; Tang-Wai, David F; Turnbull, John; Dowlatshahi, Dar; Hassan, Ayman; Casaubon, Leanne; Mandzia, Jennifer; Sahlas, Demetrios; Breen, David P; Grimes, David; Jog, Mandar; Steeves, Thomas D L; Arnott, Stephen R; Black, Sandra E; Finger, Elizabeth; Rabin, Jennifer.
Afiliación
  • Ozzoude M; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Krembil Discovery Tower, 60 Leonard Avenue, 6th floor 6KD-407, Toronto, ON, M5T 2S8, Canada.
  • Varriano B; L.C. Campbell Cognitive Neurology Unit, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Beaton D; Dr. Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
  • Ramirez J; Department of Psychology, Faculty of Health, York University, Toronto, ON, Canada.
  • Adamo S; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Krembil Discovery Tower, 60 Leonard Avenue, 6th floor 6KD-407, Toronto, ON, M5T 2S8, Canada.
  • Holmes MF; Central Michigan University College of Medicine, Mount Pleasant, MI, USA.
  • Scott CJM; Data Science & Advanced Analytic, St. Michael's Hospital, Toronto, ON, Canada.
  • Gao F; L.C. Campbell Cognitive Neurology Unit, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Sunderland KM; Dr. Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
  • McLaughlin P; Graduate Department of Psychological Clinical Science, University of Toronto Scarborough, Scarborough, ON, Canada.
  • Goubran M; L.C. Campbell Cognitive Neurology Unit, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Kwan D; Dr. Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
  • Roberts A; L.C. Campbell Cognitive Neurology Unit, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Bartha R; Dr. Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
  • Symons S; L.C. Campbell Cognitive Neurology Unit, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Tan B; Dr. Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
  • Swartz RH; Rotman Research Institute of Baycrest Centre, Toronto, ON, Canada.
  • Abrahao A; Nova Scotia Health, Halifax, NS, Canada.
  • Saposnik G; Dr. Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
  • Masellis M; Harquail Centre for Neuromodulation, Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Lang AE; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
  • Marras C; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Zinman L; Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada.
  • Shoesmith C; Queen's University, Kingston, ON, Canada.
  • Borrie M; Roxelyn and Richard Pepper Department of Communication Sciences and Disorders, Northwestern University, Evanston, IL, USA.
  • Fischer CE; School of Communication Sciences and Disorders, Faculty of Health Sciences, Western University, London, ON, Canada.
  • Frank A; Robarts Research Institute, Western University, London, ON, Canada.
  • Freedman M; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Montero-Odasso M; Rotman Research Institute of Baycrest Centre, Toronto, ON, Canada.
  • Kumar S; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Pasternak S; Department of Medicine, Division of Neurology, University of Toronto, Toronto, ON, Canada.
  • Strother SC; Heart & Stroke Foundation Canadian Partnership for Stroke Recovery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Pollock BG; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Rajji TK; Department of Medicine, Division of Neurology, University of Toronto, Toronto, ON, Canada.
  • Seitz D; Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
  • Tang-Wai DF; Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
  • Turnbull J; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Dowlatshahi D; Department of Medicine, Division of Neurology, University of Toronto, Toronto, ON, Canada.
  • Hassan A; Department of Medicine, Division of Neurology, University of Toronto, Toronto, ON, Canada.
  • Casaubon L; Edmond J Safra Program for Parkinson Disease, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.
  • Mandzia J; Department of Medicine, Division of Neurology, University of Toronto, Toronto, ON, Canada.
  • Sahlas D; Edmond J Safra Program for Parkinson Disease, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.
  • Breen DP; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Grimes D; Department of Medicine, Division of Neurology, University of Toronto, Toronto, ON, Canada.
  • Jog M; Department of Clinical Neurological Sciences, Western University, London, ON, Canada.
  • Steeves TDL; Robarts Research Institute, Western University, London, ON, Canada.
  • Arnott SR; Department of Clinical Neurological Sciences, Western University, London, ON, Canada.
  • Black SE; Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
  • Finger E; Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
  • Rabin J; Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Alzheimers Res Ther ; 15(1): 114, 2023 06 20.
Article en En | MEDLINE | ID: mdl-37340319
ABSTRACT

BACKGROUND:

Neuropsychiatric symptoms (NPS) are a core feature of most neurodegenerative and cerebrovascular diseases. White matter hyperintensities and brain atrophy have been implicated in NPS. We aimed to investigate the relative contribution of white matter hyperintensities and cortical thickness to NPS in participants across neurodegenerative and cerebrovascular diseases.

METHODS:

Five hundred thirteen participants with one of these conditions, i.e. Alzheimer's Disease/Mild Cognitive Impairment, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Parkinson's Disease, or Cerebrovascular Disease, were included in the study. NPS were assessed using the Neuropsychiatric Inventory - Questionnaire and grouped into hyperactivity, psychotic, affective, and apathy subsyndromes. White matter hyperintensities were quantified using a semi-automatic segmentation technique and FreeSurfer cortical thickness was used to measure regional grey matter loss.

RESULTS:

Although NPS were frequent across the five disease groups, participants with frontotemporal dementia had the highest frequency of hyperactivity, apathy, and affective subsyndromes compared to other groups, whilst psychotic subsyndrome was high in both frontotemporal dementia and Parkinson's disease. Results from univariate and multivariate results showed that various predictors were associated with neuropsychiatric subsyndromes, especially cortical thickness in the inferior frontal, cingulate, and insula regions, sex(female), global cognition, and basal ganglia-thalamus white matter hyperintensities.

CONCLUSIONS:

In participants with neurodegenerative and cerebrovascular diseases, our results suggest that smaller cortical thickness and white matter hyperintensity burden in several cortical-subcortical structures may contribute to the development of NPS. Further studies investigating the mechanisms that determine the progression of NPS in various neurodegenerative and cerebrovascular diseases are needed.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Trastornos Cerebrovasculares / Demencia Frontotemporal / Disfunción Cognitiva / Sustancia Blanca Tipo de estudio: Diagnostic_studies / Risk_factors_studies Idioma: En Revista: Alzheimers Res Ther Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Trastornos Cerebrovasculares / Demencia Frontotemporal / Disfunción Cognitiva / Sustancia Blanca Tipo de estudio: Diagnostic_studies / Risk_factors_studies Idioma: En Revista: Alzheimers Res Ther Año: 2023 Tipo del documento: Article